5 August 2024

IXICO plc

("IXICO" or the "Company")

Appointment of CEO

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, is pleased to announce that Bram Goorden will be appointed as Chief Executive Officer of the Company from 19 August 2024.

Bram has over 20 years leadership experience in BioPharma and precision medicine, serving in roles where he has been instrumental in shaping commercial strategies for scale, growing revenues and ultimately enabling realisation of shareholder value. He has strong CNS experience, and established networks within IXICO's target market bringing sector relevant strength to IXICO.

Bram joins having recently held C-level roles at Eagle Genomics Limited where he drove key industry alliances for their AI platform and NASDAQ listed SOPHiA Genetics Inc where he expanded their US footprint and delivered key alliances with Pharma. In previous roles as VP International Business, he expanded Foundation Medicine Inc's global presence in precision medicine including programs with major BioPharma partners, and as division CEO of US-based Prometheus Laboratories he delivered shareholder value via the integration of the company into Nestle Health Science SA. Bram has also held senior management positions within UCB Pharma SA and Eli Lilly & Co, both in the field of CNS medicine.

Bram's neuroscience experience is demonstrated at Board level through current and past roles at Mantis Photonics AB, a company providing a non-invasive method of detecting neuro-degenerative diseases through retinal image biomarker analysis and Cerecin Inc, a clinical development company focused on therapeutic approaches to treat neurodegenerative diseases. Bram started his career as a management consultant at Accenture.

Bram's appointment follows the announcement made on 12 January 2024, of Giulio Cerroni's intention to retire from his role as CEO by the end of 2024. Giulio will step down as a director of the Company on 16 August 2024. Giulio continues to be available to the Company to support an orderly hand over.

Mark Warne, Chair of the Board, commented: "I am delighted to welcome Bram to the Board as our CEO. Bram has significant track record in the commercial application of AI precision medicine solutions that is complemented by technical knowledge within neurodegenerative diseases.  As IXICO looks to return to growth, Bram's experiences provide excellent credentials to ensure IXICO also realises shareholder value.

I would like to thank Giulio for his valuable contributions over many years. Having joined IXICO in 2017, Giulio steered the company through a period of both strong growth and more challenging trading conditions.  He has overseen the development of the company's science and technology portfolio which, in combination with IXICO's operational capabilities, ensure the consistent delivery of leading services to the CNS clinical trials market."

Further disclosures required under the AIM Rules

In addition to his appointment to the Ixico Board, Bram Goorden, aged 50, holds or has held the following directorships or partnerships in the past five years. Bram currently holds no shares in the Company.

For further information please contact:

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews